GENE ONLINE|News &
Opinion
Blog

2020-09-22| Special

Spotlight: Cannabidiol (CBD) Based Medication Heralds New Promise in Neurological Therapies

by GeneOnline
Share To
Among the 100 or so phytocannabinoids that have been identified in the Cannabis sativa herb, delta 9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have been explored the most for pharmacological use. Although 33 states have approved the use of cannabis in the U.S. for medicinal purposes, the U.S. Drug Enforcement Administration recognizes it as a Schedule I drug.

This has impeded the use of cannabis in clinical research, potentially obscuring physicians and nurses about its safety, efficacy, and dosage for pharmaceutical applications through rigorous double-blinded, placebo-controlled studies. Besides, cannabinoid-containing substances obtained for research purposes are not chemically or physically representative of the legal cannabis market.

GO Prime with only $1.49 now

LATEST
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
2024-02-21
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
2024-02-21
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
2024-02-21
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
2024-02-21
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
2024-02-19
EVENT
Scroll to Top